Success Metrics

Clinical Success Rate

80.0%

Based on 4 completed trials

Completion Rate

80%(4/5)

Active Trials

0(0%)

Results Posted

25%(1 trials)

Terminated

1(20%)

Phase Distribution

Ph phase_2

20%

Ph early_phase_1

20%

Ph phase_1

60%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution5 total trials

Early Phase 1First-in-human

1(20.0%)

Phase 1Safety & dosage

3(60.0%)

Phase 2Efficacy & side effects

1(20.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

80.0%

4 of 5 finished

Non-Completion Rate

20.0%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(4)

Terminated(1)

Detailed Status

Completed4

Terminated1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

80.0%

Most Advanced

Phase 2

Trials by Phase

Early Phase 11 (20.0%)

Phase 13 (60.0%)

Phase 21 (20.0%)

Trials by Status

completed480%

terminated120%

Recent Activity

0 active trials

Showing 5 of 5

terminatedphase_2

Intra-op Detection of Occult Ovarian Carcinoma Using a Folate-Alpha Receptor Specific Fluorescent Ligand

NCT01511055

completedearly_phase_1

Clinical Trials (5)

Showing 5 of 5 trials

NCT01511055Phase 2

Intra-op Detection of Occult Ovarian Carcinoma Using a Folate-Alpha Receptor Specific Fluorescent Ligand

Terminated

NCT01778933Early Phase 1

Intraoperative Imagery of Renal Nodules With Folate-fluorescein Conjugate(EC17)

Completed

NCT01994369Phase 1

Intraoperative Imagery of Breast Cancer With Folate-FITC (EC17)

Completed

NCT01996072Phase 1

EC17 for Intraoperative Imaging for Parathyroidectomy

Completed

NCT02000778Phase 1

EC17 for Intraoperative Imaging in Occult Ovarian Cancer

Completed

All 5 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 5